Recruiting studies: Adjuvant Treatment After Trastuzumab

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subje
Phase 3 · 179 location(s) · Greenwich LifeSciences, Inc. · NCT05232916 ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathol
Phase 3 · 671 location(s) · Alliance for Clinical Trials in Oncology · NCT06876714 A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer
Phase 3 · 2 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT06830889 Circulating Tumor Cells and Treatment De-escalation After Neoadjuvant Therapy for HER2 Positive Breast Cancer
Phase 2 · 1 location(s) · AC Camargo Cancer Center · NCT04993014 Adjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer
Phase 3 · 1 location(s) · RenJi Hospital · NCT04254263 Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breas
Phase 3 · 1 location(s) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · NCT05760612

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.